LG-CHEM-LIFE-SCIENCES
7.1.2021 14:32:19 CET | Business Wire | Press release
LG Chem announced today that its Sabin-Inactivated Polio Vaccine (Sabin-IPV) Eupolio™ received World Health Organization (WHO) prequalification effective December 21st , 2020, enabling it to be supplied globally as early as this month.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005307/en/
WHO prequalification of Eupolio™ is a major milestone in ongoing efforts towards global polio eradication, as it will help close the gap between demand and supply of safe and effective Inactivated Polio Vaccine (IPV) for millions of infants in need of immunization against poliovirus.
Eupolio™ is the first Sabin-IPV to obtain WHO prequalification. The main advantage of using attenuated Sabin poliovirus strains in the production of IPV is that there is a lower biosafety risk compared to wild-type polioviruses used to manufacture conventional IPVs, which has the potential to pose a biosafety hazard in case they escape from the manufacturing facility.
LG Chem initiated the development of Eupolio™ in 2014 and invested in the construction of a state of the art WHO Global Action Plan III compliant manufacturing facility in Osong, Korea. Eupolio™ demonstrated excellent phase III results in 2019, inducing high antibody titers against both wild-type and Sabin polioviruses, which will also protect against circulating vaccine-derived polioviruses (cVDPV) that make up the majority of polio cases in recent years.
Despite global efforts to eradicate poliovirus, more cases are being reported, with its international spread declared as a Public Health Emergency of International Concern by the WHO Director-General since 2014. The situation has been exacerbated by a global shortage of IPV, where many countries have not been able to introduce IPV in their routine immunization programs as recommended by WHO.
“LG Chem will facilitate the polio endgame by delivering the much-needed doses to infants in need of safe and effective polio vaccines,” said Ji-woong Son, Head of Life Sciences at LG Chem, “and will continue to contribute to improve global health by ensuring global accessibility of such essential vaccines.”
LG Chem developed Korea's first recombinant hepatitis B vaccine, Euvax™, and has since supplied it to more than 80 countries worldwide for the past 20 years. It has consistently invested in R&D to also develop the pentavalent vaccine, Eupenta™, which was prequalified in 2016. Development of Eupolio™ was supported by the Bill & Melinda Gates Foundation, with an extended partnership to develop a hexavalent combination vaccine, total awarded grants amounting to USD 57.6 Million. LG Chem’s hexavalent vaccine currently in clinical phase II is designed to prevent diphtheria, tetanus, pertussis, hepatitis B, haemophilus influenza type B, and polio, and aims to launch in 2024.
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Partners With Cyprus Game Makers Association (CYGMA) as the Island Emerges as a Game Development Hub23.3.2026 14:00:00 CET | Press release
Strategic Partnership Equips Cyprus-Based Developers With the Commerce Infrastructure to Compete Globally Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a strategic partnership with the Cyprus Game Makers Association (CYGMA). The collaboration will provide creators and studios within the CYGMA network with hands-on support, industry expertise, and access to world-class commerce tools, helping Cyprus-based studios bring their titles to players worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323570679/en/ Graphic: Xsolla The partnership comes as Cyprus continues to attract game development talent, fueled by favorable business conditions and a growing creative community. Through its collaboration with CYGMA, Xsolla aims to accelerate momentum and expand opportunities for developers by removing commerce and distribution barriers that often p
Exein Unveils Next-Generation Runtime Security to Protect the AI-Native World23.3.2026 14:00:00 CET | Press release
Photon blocks cyberattacks before execution across physical AI and IoT, autonomous AI agents and cloud and edge infrastructure Kernel-level prevention sets a new standard beyond traditional user-space detection Builds on Exein’s position as the world’s largest runtime security provider, protecting over two billion devices Exein, the global leader in runtime cybersecurity, today unveiled Photon, a preemptive breakthrough solution that blocks cyberattacks at the point of execution. Designed for the AI-native world - where digital and physical systems are now inseparable - Photon marks a fundamental shift in how critical infrastructure protects itself. Unlike traditional cybersecurity solutions that detect threats after compromise - typically operating in user space and relying on a cloud network - Exein’s Photon operates directly inside the kernel, preventing malicious execution paths before they can run. By blocking attacks before the point of execution, the technology dramatically redu
Manhattan Associates’ 2026 Unified Commerce Benchmark Reveals the High Price of Standing Still in Retail23.3.2026 13:30:00 CET | Press release
Leaders achieve up to 2X revenue growth, but only 7% of retailers are true unified commerce leaders Manhattan Associates Inc. (NASDAQ: MANH), today announced the findings of its 2026 Global Unified Commerce Benchmark for Specialty Retail, the industry’s most comprehensive assessment of how well retailers connect digital and physical experiences to drive growth, profitability and loyalty. Conducted by Incisiv, a leading retail research firm, the Benchmark is based on real-world purchases and returns. It analyzes more than 400 specialty retailers across EMEA, LATAM and North America on 330 capabilities spanning four key experience areas: Shopping, Checkout, Fulfillment, and Service. The 2026 Benchmark reveals that while the industry has made steady progress in unified commerce maturity since 2023 when it was first launched, only 7% of retailers have achieved true unified commerce leadership while 33% are still stuck in the Basic category. Leaders are translating connected, data‑driven ye
Starr Completes Acquisition of IQUW Group23.3.2026 13:00:00 CET | Press release
Creates a stronger, more diversified global specialty platform Starr, a global investment and insurance organization, today announced that it has completed its acquisition of IQUW Group, creating a broader, more diversified specialty (re)insurance platform with enhanced capabilities across the London market, Bermuda and UK retail motor. The combined Starr business now serves more clients and brokers in more specialist classes and market segments globally. With IQUW Group, Starr has strengthened its position in the London market and established its managing agency as the ninth-largest at Lloyd’s. Importantly, Starr will continue to operate with a strong emphasis on underwriting expertise and best-in-class broker and client experience and service. Clients and brokers will benefit from a broader product offering, quick decision-making, greater capital strength and expanded global reach. Starr’s reinsurance capability is also significantly enhanced following this transaction. IQUW Re Bermu
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders23.3.2026 13:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic collaboration with Moonlight Bio, Inc., a Seattle-based biotech company pioneering advanced cell therapies. This partnership aims to develop cutting-edge cell therapies to address some of the most challenging and difficult-to-treat cancers. Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are thrilled to partner with Moonlight Bio, a pioneering leader in advanced cell therapies. This strategic collaboration leverages our proprietary off-the-shelf fully human antibody library to accelerate the development of cutting-edge cell therapies for difficult-to-treat cancers. It also demonstrates the versatility and broad applicability of Biocytogen’s antibody discovery platforms beyond traditional drug modalities. By combining our expertise,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom